keyword
MENU ▼
Read by QxMD icon Read
search

Valsartan with amlodipine

keyword
https://www.readbyqxmd.com/read/28527109/erratum-to-clinical-pharmacokinetics-of-sacubitril-valsartan-lcz696-a-novel-angiotensin-receptor-neprilysin-inhibitor
#1
Surya Ayalasomayajula, Thomas Langenickel, Parasar Pal, Sreedevi Boggarapu, Gangadhar Sunkara
Sacubitril/valsartan (LCZ696) is indicated for the treatment of heart failure with reduced ejection fraction. Absorption of sacubitril/valsartan and conversion of sacubitril (prodrug) to sacubitrilat (neprilysin inhibitor) was rapid with maximum plasma concentrations of sacubitril, sacubitrilat, and valsartan (angiotensin receptor blocker) reaching within 0.5, 1.5-2.0, and 2.0-3.0 h, respectively. With a twofold increase in dose, an increase in the area under the plasma concentration-time curve was proportional for sacubitril, ~1...
May 19, 2017: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/28490725/effects-of-valsartan-and-amlodipine-on-oxidative-stress-in-type-2-diabetic-patients-with-hypertension-a-randomized-multicenter-study
#2
Hae Jin Kim, Seung Jin Han, Dae Jung Kim, Hak Chul Jang, Soo Lim, Sung Hee Choi, Yong Hyun Kim, Dong Hyun Shin, Se Hwa Kim, Tae Ho Kim, Yu Bae Ahn, Seung Hyun Ko, Nan Hee Kim, Ji A Seo, Ha Young Kim, Kwan Woo Lee
BACKGROUND/AIMS: Oxidative stress plays an important role in the pathogenesis and progression of diabetic complications and antagonists of renin-angiotensin system and amlodipine have been reported previously to reduce oxidative stress. In this study, we compared the changes in oxidative stress markers after valsartan and amlodipine treatment in type 2 diabetic patients with hypertension and compared the changes in metabolic parameters. METHODS: Type 2 diabetic subjects with hypertension 30 to 80 years of age who were not taking antihypertensive drugs were randomized into either valsartan (n = 33) or amlodipine (n = 35) groups and treated for 24 weeks...
May 2017: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/28417439/clinical-pharmacokinetics-of-sacubitril-valsartan-lcz696-a-novel-angiotensin-receptor-neprilysin-inhibitor
#3
REVIEW
Surya Ayalasomayajula, Thomas Langenickel, Parasar Pal, Sreedevi Boggarapu, Gangadhar Sunkara
Sacubitril/valsartan (LCZ696) is indicated for the treatment of heart failure with reduced ejection fraction. Absorption of sacubitril/valsartan and conversion of sacubitril (prodrug) to sacubitrilat (neprilysin inhibitor) was rapid with maximum plasma concentrations of sacubitril, sacubitrilat, and valsartan (angiotensin receptor blocker) reaching within 0.5, 1.5-2.0, and 2.0-3.0 h, respectively. With a two-fold increase in dose, an increase in the area under the plasma concentration-time curve was proportional for sacubitril, ~1...
April 17, 2017: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/28340729/development-validation-and-comparison-of-near-infrared-and-raman-spectroscopic-methods-for-fast-characterization-of-tablets-with-amlodipine-and-valsartan
#4
Tibor Casian, Andra Reznek, Andreea Loredana Vonica-Gligor, Jeroen Van Renterghem, Thomas De Beer, Ioan Tomuță
The objective of this study was to develop, validate and compare NIR and Raman spectroscopic methods for fast characterization in terms of API content and tensile strength of fixed-dose combination tablets containing amlodipine and valsartan. For the APIs assay NIR-transmittance and Raman-reflectance methods were considered, whereas for the tensile strength assay Raman spectra were recorded in reflectance configuration and NIR spectra were recorded in both reflectance and transmittance. Multivariate calibration models (PLS) were built by applying different pre-processing methods (SNV, MSC, SD+SNV) on certain spectral regions...
May 15, 2017: Talanta
https://www.readbyqxmd.com/read/28230062/triple-combination-therapy-in-the-treatment-of-hypertension-a-review-of-the-evidence
#5
REVIEW
R Düsing, B Waeber, M Destro, C Santos Maia, P Brunel
Hypertension is a serious public health concern with inadequate control of blood pressure (BP) worldwide. Contributing factors include low efficacy of drugs, underuse of combination therapies, irrational combinations, physicians' therapeutic inertia and poor adherence to treatment. Current guidelines recommend the use of initial (dual) combination therapy in high-risk patients for immediate BP response, better short- and long-term BP control, and continued/improved patient adherence. This article aims to review the existing evidence of triple-combination therapies with respect to efficacy, safety and adherence to treatment...
February 23, 2017: Journal of Human Hypertension
https://www.readbyqxmd.com/read/28104105/effects-of-amlodipine-and-valsartan-on-blood-pressure-variability-and-pulse-wave-velocity-in-hypertensive-patients
#6
Rufeng Shi, Kai Liu, Di Shi, Qi Liu, Xiaoping Chen
OBJECTIVES: Antihypertensive therapy is effective to control blood pressure (BP) and to prevent cardiovascular events, but the further treatment strategies for patients who cannot achieve goal BP with low-dose monotherapy is still under dispute. Our study investigates the effects of high-dose amlodipine and valsartan and their low-dose combination on blood pressure variability (BPV) and pulse wave velocity (PWV) to provide references for clinical medication. MATERIALS AND METHODS: This study was a prospective, randomized, parallel, case-controlled trial performed in a medical center...
January 2017: American Journal of the Medical Sciences
https://www.readbyqxmd.com/read/28093466/effects-of-sacubitril-valsartan-versus-olmesartan-on-central-hemodynamics-in-the-elderly-with-systolic-hypertension-the-parameter-study
#7
Bryan Williams, John R Cockcroft, Kazuomi Kario, Dion H Zappe, Patrick C Brunel, Qian Wang, Weinong Guo
Effective treatment of systolic hypertension in elderly patients remains a major therapeutic challenge. A multicenter, double-blind, randomized controlled trial with sacubitril/valsartan (LCZ696), a first-in-class angiotensin receptor neprilysin inhibitor, was conducted to determine its effects versus olmesartan (angiotensin receptor blocker) on central aortic pressures, in elderly patients (aged ≥60 years) with systolic hypertension and pulse pressure >60 mm Hg, indicative of arterial stiffness. Patients (n=454; mean age, 67...
March 2017: Hypertension
https://www.readbyqxmd.com/read/28030431/efficacy-and-safety-of-sacubitril-valsartan-lcz696-add-on-to-amlodipine-in-asian-patients-with-systolic-hypertension-uncontrolled-with-amlodipine-monotherapy
#8
Ji-Guang Wang, Kimihiko Yukisada, Antonio Sibulo, Kudsia Hafeez, Yan Jia, Jack Zhang
OBJECTIVE: The objective of this study is to evaluate the efficacy and safety of sacubitril/valsartan (LCZ696, an angiotensin receptor and neprilysin inhibitor) add-on to amlodipine compared with amlodipine monotherapy in Asian patients with systolic hypertension uncontrolled with amlodipine. METHODS: Patients with mean clinic SBP at least 145 mmHg and less than 180 mmHg after a 4-week treatment with amlodipine 5 mg/day were randomized to receive LCZ696/amlodipine (200/5 mg/day) or amlodipine 5 mg/day for 8 weeks...
April 2017: Journal of Hypertension
https://www.readbyqxmd.com/read/27936949/comparison-of-valsartan-and-amlodipine-on-ambulatory-blood-pressure-variability-in-hypertensive-patients
#9
RANDOMIZED CONTROLLED TRIAL
Kazuo Eguchi, Yuki Imaizumi, Toshiki Kaihara, Satoshi Hoshide, Kazuomi Kario
We tested the hypothesis that calcium channel blockers (CCBs: amlodipine group, n = 38)) are superior to angiotensin receptor blockers (ARBs: valsartan group, n = 38) against ambulatory blood pressure variability (BPV) in untreated Japanese hypertensive patients. Both drugs significantly reduced ambulatory systolic and diastolic BP values. With regard to BPV, standard deviation (SD) in SBP did not change with the administration of either drug, but the ARB significantly increased SD in awake DBP (12 ± 4-14 ± 4 mmHg)...
2016: Clinical and Experimental Hypertension: CHE
https://www.readbyqxmd.com/read/27853163/long-term-52-week-safety-and-efficacy-of-sacubitril-valsartan-in-asian-patients-with-hypertension
#10
Ouppatham Supasyndh, Ningling Sun, Kazuomi Kario, Kudsia Hafeez, Jack Zhang
Sacubitril/valsartan (LCZ696), a first-in-class angiotensin receptor-neprilysin inhibitor, demonstrated significant reductions in office and 24 h ambulatory blood pressure (BP) over 8 weeks in Asian patients with hypertension. This 52-week extension to the 8-week core study was aimed at evaluating the long-term safety, tolerability and efficacy of sacubitril/valsartan. Patients who completed an 8-week randomized study (the core study) were enrolled in this 52-week open-label study and received sacubitril/valsartan 200 mg QD...
May 2017: Hypertension Research: Official Journal of the Japanese Society of Hypertension
https://www.readbyqxmd.com/read/27829955/efficacy-and-safety-of-a-single-pill-fixed-dose-combination-of-azilsartan-and-amlodipine
#11
Kota Motozato, Shin-Ichiro Miura, Yuhei Shiga, Takaaki Kusumoto, Keijiro Saku
BACKGROUND: Guidelines for the management of hypertension recommend the use of drugs with different mechanisms of action in antihypertensive regimens that include single-pill fixed-dose combinations of medications. There is some controversy regarding which single-pill fixed-dose combinations of angiotensin II type 1 receptor blockers (ARBs) and calcium channel blockers (CCBs) are effective at reducing blood pressure (BP). METHODS: Forty hypertensive patients who were receiving a single-pill fixed-dose combination of valsartan 80 mg/day and amlodipine 5 mg/day or irbesartan 100 mg/day and amlodipine 5 mg/day were enrolled...
December 2016: Journal of Clinical Medicine Research
https://www.readbyqxmd.com/read/27754163/sy-11-3-hypertension-in-women-more-dangerous-than-in-men
#12
Suzanne Oparil
Heart disease, stroke, and kidney failure are leading causes of death worldwide, and hypertension is a significant risk factor for each. Hypertension is less common in women, compared to men, in those younger than 45 years of age. This trend is reversed in those 65 years and older. In the US between 2011-2014, the prevalence of hypertension in women and men by age group was 6% vs 8% (18-39 years), 30% vs 35% (40-59 years), and 67% vs 63% (60 years and over). Awareness, treatment, and control rates differ between genders with women being more aware of their diagnosis (85% vs 80%), more likely to take their medications (81% vs 71%) and more frequently having controlled hypertension (55% vs 49%)...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27753873/ish-aha-2-a-case-of-chronic-indolent-pheochromocytoma-which-caused-medically-controlled-hypertension-but-treatment-resistant-diabetes-mellitus
#13
Hae-Young Lee, Chan-Soon Park, Sang-Hoon Na, Kyung-Jin Kim, Chan Joo Lee, Sungha Park
A 47-year-old woman was admitted via emergency department due to dyspnea NYHA Fc II-III aggravated for 2 months after upper respiratory infection. Her height and body weight were 161 cm / 67 kg. Initial vital signs were 110/70 mmHg - 112 BPM - 24/min - 36.5°C. Chest PA showed cardiomegaly and pulmonary congestion (Figure 1). B-natriuretic peptide level was markedly increased (2002 pg/mL, normal range ≤ 100 pg/mL). The echocardiographic examination showed severely dilated LV cavity (61/72 mm) and severe LV systolic dysfunction (EF 28%) with normal left ventricular wall thickness (9/11 mm) (Figure 2)...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27747834/real-life-effectiveness-and-safety-of-amlodipine-valsartan-single-pill-combination-in-patients-with-hypertension-in-egypt-results-from-the-excite-study
#14
Samir H Assaad-Khalil, Nashwa Nashaat
BACKGROUND: EXCITE (clinical experience of amlodipine and valsartan in hypertension) evaluated the real-world effectiveness and safety of single-pill combinations (SPCs) of amlodipine/valsartan (Aml/Val) and amlodipine/valsartan/hydrochlorothiazide (Aml/Val/HCTZ) in patients with hypertension from the Middle East and Asia. OBJECTIVE: The objective of this study was to report the results of EXCITE study from Egypt, where all patients were prescribed Aml/Val. METHODS: This was a 26-week, observational, multicenter, prospective, non-interventional, open-label study...
September 2016: Drugs—Real World Outcomes
https://www.readbyqxmd.com/read/27703364/in-vitro-and-in-vivo-postmarketing-surveillance-of-valsartan-alone-or-in-combination-with-amlodipine-or-hydrochlorothiazide-among-palestinian-hypertensive-patients
#15
Abdel Naser Zaid, Masshour Ghanem, Dua'a Shweiki, Hala Shtewi, Raja' Shaheen, Sondos Al Helaly, Zeina Khayyat, Rowa'a Al Ramahi, Sa'ed H Zyoud
OBJECTIVES: The objectives of this study were to evaluate the general quality of the most prescribed products of valsartan (VL; alone or in combination) and to evaluate their efficacy and safety among Palestinian population through in vivo postmarketing surveillance. PATIENTS AND METHODS: The first part was pharmacopeial quality control assay, including dissolution, disintegration, friability, and weight uniformity for VL. The second part was a 3-month cardiology clinics, observational, postmarketing surveillance pilot study that included 103 hypertensive patients who were prescribed 80 mg or 160 mg of VL as monotherapy or combination therapy...
2016: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/27643118/sy-11-3-hypertension-in-women-more-dangerous-than-in-men
#16
Suzanne Oparil
Heart disease, stroke, and kidney failure are leading causes of death worldwide, and hypertension is a significant risk factor for each. Hypertension is less common in women, compared to men, in those younger than 45 years of age. This trend is reversed in those 65 years and older. In the US between 2011-2014, the prevalence of hypertension in women and men by age group was 6% vs 8% (18-39 years), 30% vs 35% (40-59 years), and 67% vs 63% (60 years and over). Awareness, treatment, and control rates differ between genders with women being more aware of their diagnosis (85% vs 80%), more likely to take their medications (81% vs 71%) and more frequently having controlled hypertension (55% vs 49%)...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27643110/ish-aha-2-a-case-of-chronic-indolent-pheochromocytoma-which-caused-medically-controlled-hypertension-but-treatment-resistant-diabetes-mellitus
#17
Hae-Young Lee, Chan-Soon Park, Sang-Hoon Na, Kyung-Jin Kim, Chan Joo Lee, Sungha Park
A 47-year-old woman was admitted via emergency department due to dyspnea NYHA Fc II-III aggravated for 2 months after upper respiratory infection. Her height and body weight were 161 cm / 67 kg. Initial vital signs were 110/70 mmHg - 112 BPM - 24/min - 36.5°C. Chest PA showed cardiomegaly and pulmonary congestion (Figure 1). B-natriuretic peptide level was markedly increased (2002 pg/mL, normal range ≤ 100 pg/mL). The echocardiographic examination showed severely dilated LV cavity (61/72 mm) and severe LV systolic dysfunction (EF 28%) with normal left ventricular wall thickness (9/11 mm) (Figure 2)...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27566613/development-and-validation-of-highly-sensitive-stability-indicating-spectrofluorimetric-method-for-determination-of-amlodipine-in-pharmaceutical-preparations-and-human-plasma
#18
Abdel-Maaboud I Mohamed, Mahmoud A Omar, Mohamed A Hammad, Abobakr A Mohamed
A highly sensitive and simple spectrofluorimetric method was developed for the determination of Amlodipine besylate (AML) in its pharmaceutical formulations and spiked human plasma. The proposed method is based on the investigation of the fluorescence spectral behaviour of AML in Tween-80 micellar system. In aqueous solution, the fluorescence intensity of AML was greatly enhanced (160 %) in the presence of Tween-80. The fluorescence intensity was measured at 427 nm after excitation at 385 nm. The fluorescence-concentration plot was rectilinear over the concentration range 0...
August 26, 2016: Journal of Fluorescence
https://www.readbyqxmd.com/read/27542885/improved-insulin-sensitivity-with-angiotensin-receptor-neprilysin-inhibition-in-individuals-with-obesity-and-hypertension
#19
J Jordan, R Stinkens, T Jax, S Engeli, E E Blaak, M May, B Havekes, C Schindler, D Albrecht, P Pal, T Heise, G H Goossens, T H Langenickel
Natriuretic peptide (NP) deficiency and sustained renin-angiotensin system activation are associated with impaired oxidative metabolism and predispose to type-2 diabetes. We hypothesized that sacubitril/valsartan (LCZ696), which augments NP through neprilysin inhibition while blocking angiotensin II type-1 (AT1 )-receptors, improves insulin sensitivity, lipid mobilization, and oxidation. After 8 weeks of treatment of obese patients with hypertension, sacubitril/valsartan 400 mg q.d., but not amlodipine 10 mg q...
August 20, 2016: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/27515419/on-the-top-of-arb-n-l-type%C3%A2-ca-channel-blocker-leads-to-less-elevation-of-aldosterone
#20
Tadashi Konoshita, Saori Kaeriyama, Machi Urabe, Takahiro Nakaya, Mika Yamada, Mai Ichikawa, Katsushi Yamamoto, Satsuki Sato, Michiko Imagawa, Miki Fujii, Yasukazu Makino, Yasuo Zenimaru, Shigeyuki Wakahara, Jinya Suzuki, Tamotsu Ishizuka, Hiroyuki Nakamura
The activation of the renin-angiotensin system (RAS) is one of the unfavourable characteristics of calcium channel blocker (CCB). N type calcium channel is thought to be involved in renin gene transcription and adrenal aldosterone release. Accordingly, N/L type CCB has a possibility of less elevation of plasma aldosterone concentrations (PAC) among CCBs. In a monotherapy study, we had already demonstrated that N/L type CCB leads to less activation of the RAS compared with L type CCB. The objective of this study is to substantiate the hypothesis that at the condition of additive administration on the top of an angiotensin receptor blocker (ARB), still N/L type CCB leads to less elevation of PAC compared with L type one...
October 2016: Bioscience Reports
keyword
keyword
83478
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"